Marijuana's potential in neurodegenerative diseases: an editorial

Arosh S. Perera Molligoda Arachchige; Arosh S. Perera Molligoda Arachchige

doi:10.3934/Neuroscience.2023014

AIMS Neuroscience

2023, Volume 10, Issue 2: 175-177. doi: 10.3934/Neuroscience.2023014

Previous Article Next Article

Editorial Special Issues

Marijuana's potential in neurodegenerative diseases: an editorial

Arosh S. Perera Molligoda Arachchige ^,

Department of Biomedical Sciences, Humanitas University, Milan, Italy

Received: 02 June 2023 Revised: 18 June 2023 Accepted: 20 June 2023 Published: 25 June 2023

Citation: Arosh S. Perera Molligoda Arachchige. Marijuana's potential in neurodegenerative diseases: an editorial[J]. AIMS Neuroscience, 2023, 10(2): 175-177. doi: 10.3934/Neuroscience.2023014

Related Papers:

Conflicts of interest

The author has no conflicts of interest to declare.

References

[1]	Bhunia S, Kolishetti N, Arias AY, et al. (2022) Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol 13: 989717. https://doi.org/10.3389/fphar.2022.989717
[2]	Atakan Z (2012) Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharm 2: 241-254. https://doi.org/10.1177/2045125312457586
[3]	Sarne Y, Asaf F, Fishbein M, et al. (2011) The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Brit J Pharmacol 163: 1391-1401. https://doi.org/10.1111/j.1476-5381.2011.01280.x
[4]	Coles M, Watt G, Kreilaus F, et al. (2020) Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APPSwe/PS1ΔE9 Transgenic Female Mice. Front Pharmacol 11: 587604. https://doi.org/10.3389/fphar.2020.587604
[5]	Babayeva M, Assefa H, Basu P, et al. (2016) Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis 2016: 1279042. https://doi.org/10.1155/2016/1279042
[6]	Lacroix C, Alleman-Brimault I, Zalta A, et al. (2022) What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?. Front Pharmacol 13: 883987. https://doi.org/10.3389/fphar.2022.883987
[7]	Mead A (2019) Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States. Front Plant Sci 10: 697. https://doi.org/10.3389/fpls.2019.00697
[8]	Brown JD, Winterstein AG (2019) Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med 8: 989. https://doi.org/10.3390/jcm8070989
[9]	Pagano C, Navarra G, Coppola L, et al. (2022) Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci 23: 3344. https://doi.org/10.3390/ijms23063344

Reader Comments

Your name:*

Email:*
© 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)